FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / News / Read News

Print

Athyrium Capital Provides $20MM Term Loan to InnoPharma

November 14, 2013, 07:21 AM
Filed Under: Pharmaceuticals

InnoPharma, Inc. announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the company's ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction.

Navneet Puri, Ph.D., president & CEO of InnoPharma, commented, "This new financing will enhance InnoPharma's ability to continue to grow and expand our product portfolio by providing greater financial flexibility. Athyrium's understanding of our business and focus on long-term results makes them an excellent strategic fit for InnoPharma."

"We are thrilled to help fuel InnoPharma's ongoing growth with long-term, minimally dilutive capital," said Laurent Hermouet, a partner at Athyrium Capital. "A strong track record of value creation and a rapidly maturing product portfolio made partnering with InnoPharma a compelling proposition."

InnoPharma is a sterile product development company, focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms.

Athyrium Capital Management, LLC is an asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium invests across all healthcare verticals including biopharma, medical devices and products, and healthcare services and partners with management teams to implement creative financing solutions to companies' capital needs.







Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.